The TOBI Podhaler is a prescription medication designed for the management of bacterial infections in patients with cystic fibrosis. It contains the active ingredient tobramycin, which is an aminoglycoside antibiotic. This medication is specifically formulated for inhalation using a Podhaler device, which delivers the antibiotic directly to the lungs, targeting the bacteria responsible for infections in cystic fibrosis patients. The TOBI Podhaler is typically used in individuals six years of age and older who are known to have Pseudomonas aeruginosa in their lungs. By directly targeting the lungs, it aims to reduce bacterial load, decrease lung infections, and improve lung function, thereby enhancing the quality of life for those with cystic fibrosis.